[A retrospective therapeutic study of neurocryptococcosis in 112 AIDS and non-AIDS patients] NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[A retrospective therapeutic study of neurocryptococcosis in 112 AIDS and non-AIDS patients]

Rev Soc Bras Med Trop. 1992 Oct-Dec;25(4):241-6. Unique Identifier : AIDSLINE MED/94052879
de Campos EP; Carvalho VO; Marinho SF; Kushnaroff TM; Galvao PA; Padovani CR; Hospital Emilio Ribas, Sao Paulo, Brasil.

Abstract: A total of 112 AIDS and no AIDS cryptococcosis patients admitted at Emilio Ribas Hospital--Sao Paulo, Brazil, were treated with amphotericin B (AMB) or amphotericin B and 5 fluorocytosine (5FC). Age, race, predisposing and epidemiological factors, respiratory symptoms were evaluated. Goodman tests applied in three patients groups (I, II and III) with associate or unique therapy revealed: 1. prognostic factors: leukocytes ang glucose showed similar response in groups I, II and III and protein spinal fluid after 1.5g/AMB; 2. India ink tests and Cryptococcus culture were often positive until 1.0g/AMB; 3. significant hypokalemia during monotherapy. Hypo and hyperkalemia had similar data in associate therapy; 4. significant difference in adverse reactions often appeared above 0.7g AMB/250g 5FC; 5. early and late death were common in group III (unique) and group I (no AIDS) and III (2.5 to 4.0g) respectively; 6. similar remission and deaths were verified in AIDS/cryptococcosis. Conclusions: adverse reactions were observed above 0.75g/AMB plus 250g 5FC. Association was important in initial therapy and AMB maintenance permitted late relapses.
Keywords: Amphotericin B/THERAPEUTIC USE AIDS-Related Opportunistic Infections/DIAGNOSIS/*DRUG THERAPY/ EPIDEMIOLOGY Brazil/EPIDEMIOLOGY Central Nervous System Diseases/DIAGNOSIS/*DRUG THERAPY/ EPIDEMIOLOGY Comparative Study Cryptococcosis/DIAGNOSIS/*DRUG THERAPY/EPIDEMIOLOGY Drug Therapy, Combination English Abstract Flucytosine/THERAPEUTIC USE Human Retrospective Studies JOURNAL ARTICLEKWDamphotericinb/therapeuticuseaids-relatedopportunisticinfections/diagnosis/KWDdrugtherapy/epidemiologybrazil/epidemiologycentralnervoussystemdiseases/diagnosis/KWDdrugtherapy/epidemiologycomparativestudycryptococcosis/diagnosis/KWDdrugtherapy/epidemiologydrugtherapy,combinationenglishabstractflucytosine/therapeuticusehumanretrospectivestudiesjournalarticle
940228
M9420806

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .